Press Center

Press Contacts

Erika Trahan
Investors
240-268-2022
Amy Speak
Media
617-420-2461
Edna Kaplan
Media
617-974-8659

About

For a complete list of our news releases, please visit go to https://ir.novavax.com/press-releases

Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the viru...

For a complete list of our news releases, please visit go to https://ir.novavax.com/press-releases

Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Resources (Files)

Novavax-Logo-Stacked-Tag-2015 (2) copy.jpg

Bios

Mr. Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. and the MdBio Foundation. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.
https://cdn.filestackcontent.com/Qw04Z5ugTyiW48sxW0vt
Stanley C. Erck
President and Chief Executive Officer
View more >>
Dr. Glenn is the president of research and development and leads the discovery, clinical, and regulatory teams. He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants. He has led the development of products from concept to late-stage clinical development, including COVID-19, RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch, and participated in other programs including the development of a malaria vaccine. He is the cofounder of IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He worked for Intercell from 2008 to 2010. He is the coauthor of more than 100 peer-reviewed scientific publications. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997. Dr. Glenn received a bachelor of arts degree in biology and chemistry from Whitman College in Washington and a doctor of medicine degree from Oral Roberts University School of Medicine in Oklahoma.
https://cdn.filestackcontent.com/9Oe3BqGbS9aWCNgY7qyr
Gregory Glenn, M.D.
President. Research and Development
View more >>
Mr. Trizzino is executive vice president, chief business officer, and chief commercial officer with responsibility for all pre-commercial and commercial launch strategy and execution, financial reporting, corporate funding, and investor/public relations. He previously served as senior vice president of commercial operations beginning in 2014. Mr. Trizzino originally joined Novavax in 2009 with a broad range of experiences in small-to-large, publicly held companies. He has an extensive background in the vaccine market with previous roles overseeing commercialization, vaccine policy, strategic development, business development, financing, investor relations, and public relations. In 2011, Mr. Trizzino joined Immunovaccine as its CEO and successfully led the company into clinical development of its lead candidate while securing the required funding commitments in the equity market as well as non-dilutive sources. Prior to his tenures at Novavax and Immunovaccine, Mr. Trizzino had leadership responsibilities at MedImmune, LLC (an AstraZeneca company), ID Biomedical, and Henry Schein, Inc., which were all companies focused on infectious disease vaccine markets. Mr. Trizzino received a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.
https://cdn.filestackcontent.com/zUQpx9tWTsCmfT5MGsxa
John J. Trizzino
Executive Vice President, Chief Commercial Officer and Chief Business Officer
View more >>

Video

B-roll footage for use in media reporting
Download

Social Accounts